| Name | Pulocimab |
|---|
| Description | Pulocimab is an anti-VEGFR2 monoclonal antibody (mAb). Pulocimab can be used for the research of cancers[1]. |
|---|---|
| Related Catalog | |
| Target |
VEGFR2 |
| References |
[1]. Keam SJ. Cadonilimab: First Approval. Drugs. 2022 Aug;82(12):1333-1339. |
| No Any Chemical & Physical Properties |